New pill for rare bone marrow cancer shows promise in shrinking spleens

NCT ID NCT07317700

Recruiting now Disease control Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jan 09, 2026 · Last updated May 15, 2026 · Updated 28 times

Summary

This study tests a new drug called flonoltinib maleate for people with intermediate- or high-risk myelofibrosis, a rare bone marrow disorder. The main goal is to see if the drug can shrink an enlarged spleen by at least 35% and reduce symptoms like pain and fatigue. About 105 adults aged 18-80 will take either the new drug or an existing treatment to compare results.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MF are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS)
RECRUITING

Tianjin, Tianjin Municipality, 300052, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
West China Hospital Sichuan University
RECRUITING

Chengdu, Sichuan, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MF